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New pyranonaphthoquinone derivatives were synthesized and investigated for their activity against
Trypanosoma brucei, Leishmania major, and Toxoplasma gondii parasites. The pentafluorophenyl derivative was
efficacious against T. brucei with single digit micromolar EC50 values and against T. gondii with even sub-
micromolar values. The 3-chloro-4,5-dimethoxyphenyl derivative showed an activity against amastigotes of
Leishmania major parasites comparable to that of amphotericin B. In addition, antioxidant activities were
observed for the bromophenyl derivatives, and their redox behavior was studied by cyclovoltammetry. Anti-
parasitic and antioxidative activities of the new naphthoquinone derivatives appear uncorrelated.
Keywords: lawsone, neglected tropical diseases, pyran, biological activity.
Introduction
Infections of immune-compromised patients and new-
born children with the world-wide occurring toxoplas-
mosis (caused by Toxoplasma gondii parasites) can
lead to severe complications and, thus, efficient drugs
for the treatment of toxoplasmosis are necessary.[1] In
addition, neglected tropical diseases (NTDs) pose an
eminent danger to people living or working in affected
territories.[2,3] Human African trypanosomiasis (HAT,
sleeping sickness) and leishmaniasis are NTDs which
can ultimately lead to death of untreated patients.
Trypanosoma brucei gambiense (T. b. gambiense, in
West and Central Africa) and T. b. rhodesiense (in East
Africa) are the two prevalent forms of trypanosomes
which are responsible for sleeping sickness in humans
while the Nagana disease of cattle (animal trypanoso-
miasis) is mainly caused by T. b. brucei.[4,5] The
diamidine pentamidine and the urea derivative sur-
amin are drugs only applicable for patients with early
stage sleeping sickness, late stages were treated with
highly toxic arsenics such as melarsoprol for a long
time.[6] Meanwhile, the less toxic ornithine derivative
eflornithine in combination with the nitrofuran nifurti-
mox (nifurtimox-eflornithine combination treatment,
NECT) has replaced melarsoprol for the treatment of
late stage T. b. gambiense infections (g-HAT).[6] The
nitroimidazole fexinidazole was the first orally active
drug which is applied for the treatment of stage 1 and
stage 2 g-HAT.[5] The benzoxaborole derivative acozi-
borole is currently tested in phase 2/3 clinical trials
with stage 2 g-HAT patients.[5] Leishmaniasis is
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clinically subdivided into the cutaneous leishmaniasis
(CL), mucocutaneous leishmaniasis (MCL) and visceral
leishmaniasis (VL) forms, which show different clinical
outcomes. VL is caused by Leishmania infantum (L.
infantum) and L. donovani protozoal parasites and
eventually leads to death resulting into a severe
medical problem in regions where VL is endemic, e.g.,
in South Asia, Africa, Latin America and the Mediterra-
nean region.[7] The liposomal formulation of the
natural polyene macrolide amphotericin B (AmBisome)
and combinations of AmBisome with the phospholipid
miltefosine are currently applied for the treatment of
VL.[7] The skin damaging CL form, which is caused by
various Leishmania species such as L. major, L. tropica,
L. mexicana, L. amazonensis etc., is the most wide-
spread form of leishmaniasis diseases with 0.7–
1 million predominantly young patients every year.[8,9]
Although CL is usually not lethal, it causes severe and
disfiguring skin lesions and affected persons are often
stigmatized.[10,11] Current treatment options for CL
patients include pentavalent antimonials (sodium
stibogluconate, meglumine antimoniate), miltefosine,
amphotericin, and pentamidine. Recent works dis-
closed interesting preclinical results for benzoxaborole,
nitroimidazoles and aminopyrazoles as well as for the
antimonial drug activity enhancer D35 (a CpG
oligonucleotide).[9,12] Aside of the toxicity of the
currently applied drugs, the emergence of drug-
resistant parasite forms poses a growing problem to
the clinician and, thus, the search for new potent anti-
parasitic drugs is ongoing. The treatment of trypano-
somiasis and leishmaniasis with natural products or
with drugs derived from them appears promising.[3,13]
Naphthoquinones represent a significant group of
secondary metabolites of plants and lichens with a
variety of biological activities such as antioxidant and
trypanocidal activities.[3,13–15] The natural 2-hydroxy-
1,4-naphthoquinone (lawsone, 1a) isolated from the
Henna plant Lawsonia inermis showed biological
activities including antibacterial effects and was
applied as starting material for quinone drug candi-
dates such as lapachol and atovaquone (ATO).[3,13–16]
Modified lawsone derivatives with antitumor and
antifungal activities are also known.[3,17,18] Quite a few
lawsone derivatives were found efficacious against
various parasites including Plasmodium falciparum,
Leishmania donovani, Trypanosoma cruzi and Toxoplas-
ma gondii.[3,19–23] Our own previous works have led to
the identification of lawsone Mannich bases and
naphthoquinone derivatives (1b–1d) with reasonable
activities against Trypanosoma brucei, Entamoeba his-
tolytica, L. major or T. gondii (Figure 1).[3,24,25] The fusion
of the lawsone scaffold with heterocyclic rings such as
pyrans can be another promising method in order to
obtain new active compounds based on lawsone and
various anti-tumor active derivatives as well as tumor
cell senescence-inducing complexes were already
identified (1e).[26,27] In continuation of these previous
reports, we present new lawsone-derived pyranonaph-
thoquinone derivatives and their antioxidant and anti-
parasitic activities against T. brucei, L. major and T.
gondii.
Results and Discussion
Compounds 2a–2o were prepared by Knoevenagel
reaction of malononitrile and the respective aryl
aldehyde under basic conditions followed by Michael
addition of lawsone (1a) and ring-closure to the pyran
ring in a multi-component one-pot reaction
Figure 1. Lawsone (1a), selected anti-parasitic derivatives (1b–1d), and anti-tumor active pyran (1e).
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(Scheme 1).[25,26] Compounds 2a–2o were obtained as
yellow, brown or red-orange solids in moderate yields.
The compounds 2a–2o were tested against T.
gondii parasites and their activities were compared
with those against non-malignant Vero cells (Table 1).
Except for 2a and 2c, all test compounds exhibited
distinct activity against T. gondii. Compound 2h
showed the highest activity in the sub-micromolar
range (EC50=0.7 μM) and a reasonable selectivity (SI=
19.1). Compounds 2g and 2o showed similar selectiv-
ities (SI=19.6 for 2g, 22.1 for 2o). Considerably higher
selectivities were observed for 2d (SI=34.5), 2f (SI=
34.9), and 2l (SI=41.4). Although the selectivity of
these compounds is lower when compared with the
selectivity of the approved drug ATO, they were less
toxic than ATO against Vero cells and, thus, they can
be less toxic alternatives to ATO treatment.
Next, compounds 2a–2o were investigated against
L. major promastigotes and amastigotes and their
activities were compared with those against non-
malignant Vero cells (Table 2). Compound 2b showed
excellent activity against L. major amastigotes (EC50=
<0.5 μM) and, thus, 2b was at least comparably active
when compared with the approved drug amphotericin
B (AmB) in this regard. However, 2b was also quite
toxic to Vero cells (i. e., it was almost as toxic as
doxorubicin) leading to a relatively low selectivity
when compared with AmB.[28] In addition, compounds
2a,2e,2h,2i, and 2m showed activities against the
amastigotes with EC50 values below 10 μM. Com-
pounds 2d (SI=4.22) and 2o (SI=5.26) revealed the
highest selectivities for L. major amastigotes. Com-
pound 2h also showed moderate activity against L.
major promastigotes (EC50=15.3 μM). However, the
activity of the test compounds 2a–2o against promas-
tigotes was distinctly lower when compared with their
activities against amastigotes.
Selected compounds were also tested against T. b.
brucei (Table 3). Pentamidine served as positive control
here.[29] Compound 2h showed the highest activities
against the T. b. brucei cells followed by 2f and 2a. The
highest selectivity was observed for 2f (SI=12.8).
Compounds 2b,2c, and 2m were inactive at doses up
to 10 μM.
The antioxidant activities of selected compounds
2a–2f,2h,2m and 2n were evaluated using the 1,1-
diphenyl-2-picrylhydrazil (DPPH) assay (Table 4). The
radical derivative DPPH is a radical scavenger and
functions as a trap for other radicals and, thus, it is the
functional compound of common antioxidant
assays.[30–32] Compounds 2a and 2c showed distinctly
higher antioxidant activities when compared with the
other test compounds. Both compounds were also
Scheme 1. Synthesis of compounds 2a–2o.
Table 1. Antitoxoplasmal activity of compounds 2a–2o as EC50
(effective concentration that causes 50% inhibition for T. gondi
in μM)[a], while IC50 is the inhibition concentration for 50% of
the Vero (African green monkey kidney epithelial in μM). ATO







2a 131�13 4.1�0.6 0.03
2b 1.7�0.2 0.7�0.08 0.43
2c 10.6�1.7 6.0�0.72 0.57
2d 1.7�0.18 59.8�7.4 34.5
2e 2.5�0.3 17.1�2.3 6.92
2f 2.2�0.25 76.6�8.7 34.9
2g 1.8�0.22 35.8�4.4 19.6
2h 0.7�0.1 13.7�1.5 19.1
2i 2.8�0.32 17.4�2.4 6.26
2j 4.5�0.46 45.1�6.2 9.94
2k 3.1�0.38 30.3�3.9 9.92
2l 1.3�0.5 54.6�6.2 41.4
2m 1.4�0.42 9.1�1.4 6.44
2n 1.4�0.53 17.9�2.1 12.64
2o 2.8�0.35 62.7�6.0 22.1
ATO 0.07�0.004 9.5�1.54 136
Doxorubicin – 0.4�0.01[c] –
[a] Values are the average of three repeated reading for each
test�SE. Which were obtained from concentration-response
curves by measuring the percentage of vital cells relative to
untreated group after 3 days of incubation. [b] Selectivity index
(SI) calculated by dividing IC50 over EC50 of the corresponding
values. [c] Value is taken from ref. 28.
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more active than the known antioxidant ascorbic acid.
There seems to be no or just a marginal correlation
between antioxidant activity and anti-parasitic activity
of the test compounds.
The cell-independent redox properties of lawsone
derivatives 2a to 2o were studied by cyclic voltamme-
try (Figure S1–S7). 2a gave rise to a pair of peaks at
  358 mV (ipa   0.889 μA) and   556 mV (ipc 1.792 μA)
indicative of a three-electron transfer redox couple
with E1/2=   457 mV. While 2c and 2h showed similar
redox couples with almost the same ~E values, these
compounds displayed another irreversible cathodic
peak between   1004 mV and 1050 mV with different
current values (ipc 0.3104 μA in case of 2c). Such a
redox behavior was reported for other lawsone
derivatives and the redox couple at E1/2=   457 mV
can be assigned to the conversion of naphthoquinone
(NQ) to naphthosemiquinone (NSQ) (NQNSQ), while
the irreversible peak at 1050 mV can be assigned to
the following 2e  reduction to the catechol form
(NSQ!CAT).[33–35] The shift of this redox couple
towards a more negative potential when compared to
the parent lawsone compound can be attributed to
the changes occurring in the electron density based
Table 2. Antileishmanial activity of compounds 2a–2o as EC50 (effective concentration that causes 50% inhibition for L. major
amastigotes and promastigotes in μM)[a], AmB was used as positive control.
Compound EC50 promastigotes EC50 amastigotes SI Vero/promastigotes
[b] SI Vero/amastigotes[b]
2a 49.2�5.2 8.4�1.1 0.08 0.49
2b 34.1�4.4 <0.5 0.02 >1.5
2c 22.3�3.1 35.8�4.3 0.27 0.17
2d 146�16.5 14.2�1.6 0.41 4.22
2e 37.9�4.7 7.4�0.9 0.45 2.31
2f 86.5�9.1 31.3�3.4 0.89 2.45
2g 25.6�3.6 11.3�0.9 1.40 3.19
2h 15.3�1.9 5.7�0.8 0.89 2.38
2i 35.8�4.0 9.8�1.1 0.49 1.77
2j 98.0�10.1 34.2�4.7 0.46 1.32
2k 46.4�5.2 24.5�3.9 0.65 1.24
2 l 84.1�9.3 22.2�2.8 0.65 2.46
2m 29.4�3.6 7.9�1.0 0.31 1.15
2n 37.9�4.5 26.6�2.6 0.47 0.67
2o 41.2�5.0 11.9�2.1 1.52 5.26
AmB 0.83�0.09 0.47�0.06 9.6 16.4
[a] Values are the average of three repeated reading for each test � SE. Which were obtained from concentration-response curves by
measuring the percentage of vital cells relative to untreated group after 3 days of incubation. [b] Selectivity index (SI) calculated by
dividing IC50 (from Table 1) over EC50 of the corresponding values.
Table 3. Antitrypanosomal activity of compounds 2a–2c,2f,2h
and 2m as EC50 (effective concentration that causes 50%
inhibition for T. b. brucei in μM)[a], pentamidine was used as
positive control.









[a] Values are the means of at least three independent
experiments (SD�15%). They were derived from concentra-
tion–response curves obtained by measuring the percentage of
vital cells relative to untreated controls after 72 h. [b] Selectivity
index calculated from the corresponding IC50 values for the
Vero cells and the IC50 values for T. b. brucei.
[c] Value is taken
from ref. [29].
Table 4. Inhibitory concentrations IC50 of ascorbic acid (pos-
itive control) and test compounds 2a–2f,2h,2m, and 2n when
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on the bromine atoms of 2a and 2c. The electron
distributions in redox active ligands were correlated
with a preferential reduction of certain ligands.[36–38]
The π-orbital of the benzosemiquinone-type radical
ligand of 2c having a large overlap area might
contribute to its greater ROS producing effects and,
thus, showed the highest antioxidant activity com-
pared to the other test compounds. In case of 2d, a
large gain in the current (ipc 1.3047 μA and ipa
  1.4905 μA) was probably due to the electron with-
drawing effects of the fluorine atom and, thus, a fast
electron transfer was facilitated (Figure S1).[36] Com-
pound 2h showed a redox couple at E1/2=   428.5 mV
with high current values (ipc 1.9638 μA and ipa
  1.0944 μA).
Conclusions
New lawsone-derived compounds were identified as
anti-parasitic and antioxidant agents. The high anti-
parasitic activities of 2h against T. brucei and T. gondii
warrant a further investigation of its effects on these
parasites and other protozoal parasites such as
Plasmodium species. The highest antioxidant activities,
i. e., the strongest suppression of radical formation,
were observed for compounds 2a and 2c, which
showed relatively weak activities in the anti-parasitic
assays (except for 2a against T. brucei) and so there is
apparently no strong correlation between antioxidant
and anti-parasitic activities of the test compounds.
Experimental Section
General
Starting materials and pure solvents were purchased
from common providers and used without further
purification. IR spectra were measured on a PerkinElm-
er Spectrum One FT-IR spectrophotometer equipped
with an ART sampling unit. NMR spectra were
measured on a Bruker Avance 300 spectrometer and
chemical shifts (δ) are given in parts per million (ppm)
downfield from Me4Si as internal standard. Coupling
constants (J) are given in Hz. Mass spectra were
measured on a Varian MAT 311A (EI). Elemental





oxybenzaldehyde (245 mg, 1.0 mmol) and malononi-
trile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL)
and three drops of Et3N were added. The reaction
mixture was stirred at room temperature for 30 min. 2-
Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was
added, and the reaction mixture was stirred at room
temperature for 16 h. The formed precipitate was
collected, washed with MeCN and n-hexane and dried
in vacuum. Yield: 262 mg (0.56 mmol, 56%). Orange
solid. M.p. 250–251 °C. IR: 3392, 3319, 3256, 3222,
3201, 3017, 2989, 2940, 2825, 2201, 1666, 1655, 1637,
1607, 1591, 1567, 1488, 1460, 1442, 1403, 1363, 1316,
1302, 1278, 1241, 1226, 1206, 1177, 1136, 1077, 1037,
1001, 949, 866, 819, 769, 747, 732, 721, 712, 680. 1H-
NMR (300 MHz, (D6)DMSO)): 3.70 (3 H, s), 3.81 (3 H, s),
4.61 (1 H, s), 7.01 (1 H, s), 7.11 (1 H, s), 7.36 (2 H, s),
7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). 13C-NMR (75.5 MHz,
(D6)DMSO)): 36.2, 56.2, 57.1, 60.0, 112.2, 116.7, 119.3,
120.8, 123.1, 125.8, 126.0, 130.8, 131.1, 134.1, 134.4,
141.2, 144.6, 149.3, 153.3, 158.3, 176.8, 182.7; EI-MS:
468 (100) [M+ ], 466 (97) [M+ ], 437 (11), 435 (11), 387
(72), 251 (92). Anal. calc. for C22H15BrN2O5 (467.28): C




oxybenzaldehyde (200 mg, 1.0 mmol) and malononi-
trile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL)
and three drops of Et3N were added. The reaction
mixture was stirred at room temperature for 30 min. 2-
Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was
added, and the reaction mixture was stirred at room
temperature for 16 h. The formed precipitate was
collected, washed with H2O/MeCN and dried in
vacuum. Yield: 200 mg (0.47 mmol, 47%). Orange
solid. M.p. 306–307 °C. IR: 3393, 3323, 3256, 3222,
3200, 2991, 2941, 2827, 2202, 1668, 1655, 1638, 1592,
1572, 1492, 1448, 1428, 1417, 1404, 1364, 1341, 1331,
1318, 1303, 1282, 1242, 1228, 1207, 1179, 1161, 1094,
1079, 1046, 1028, 1001, 949, 868, 851, 844, 818, 7973
784, 771, 752, 733, 722, 697, 682, 631, 602; 1H-NMR
(300 MHz, (D6)DMSO) ): 3.71 (3 H, s), 3.81 (3 H, s), 4.62
(1 H, s), 6.9–7.0 (2 H, m), 7.35 /2 H, s), 7.8–7.9 (3 H, m),
8.0–8.1 (1 H, m). 13C-NMR (75.5 MHz, (D6)DMSO)) 36.2,
56.2, 57.1, 60.1, 111.5, 119.2, 120.4, 120.7, 125.8, 126.0,
126.8, 130.8, 131.0, 134.1, 134.4, 140.6, 143.6, 149.3,
153.4, 158.3, 176.8, 182.6; EI-MS: 424 (34) [M+ ], 422
(100) [M+ ], 387 (63), 251 (77). Anal. calc. for
C22H15ClN2O5 (422.82): C 62.50, H 3.58, N 6.63; found: C
62.29, H 3.46, N 6.46.
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oxybenzaldehyde (293 mg, 1.0 mmol) and malononi-
trile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL)
and three drops of Et3N were added. The reaction
mixture was stirred at room temperature for 30 min. 2-
Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was
added and the reaction mixture was stirred at room
temperature for 16 h. The formed precipitate was
collected, washed with MeCN and n-hexane and dried
in vacuum. Yield: 260 mg (0.50 mmol, 50%). Orange-
red solid. M.p. 267 °C. IR: 3414, 3323, 3281, 3253, 3211,
3194, 2201, 1658, 1638, 1606, 1594, 1547, 1471, 1417,
1401, 1362, 1334, 1300, 1262, 1203, 1183, 1100, 1074,
1040, 1025, 991, 948, 800, 782, 733, 717, 695, 668; 1H-
NMR (300 MHz, CDCl3/(D6)DMSO)): 3.74 (3 H, s), 4.60
(1 H, s), 6.85 (2 H, s), 7.40 (2 H, s), 7.7–7.8 (2 H, m), 7.9–
8.0 (1 H, m), 8.0–8.1 (1 H, m). 13C-NMR (75.5 MHz,
CDCl3/(D6)DMSO)): 35.3, 56.8, 59.9, 117.6, 118.4, 121.5,
125.9, 126.0, 129.9, 130.7, 131.7, 133.6, 134.2, 140.9,
148.1, 152.6, 158.6, 176.4, 181.9. EI-MS: 518 (40) [M+ ],
516 (72) [M+ ], 514 (40) [M+ ], 437 (16), 435 (15), 251
(100). Anal. calc. for C21H12Br2N2O4 (516.15): C 48.87, H
2.34, N 5.43; found: C 48.69, H 2.24, N 5.30.
2-Amino-4-(2-fluorophenyl)-5,10-dihydro-5,10-
dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile (2d).
2-Fluorobenzaldehyde (124 mg, 1.0 mmol) and malo-
nonitrile (70 mg, 1.0 mmol) were dissolved in MeCN
(5 mL) and three drops of Et3N were added. The
reaction mixture was stirred at room temperature for
30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg,
1.0 mmol) was added and the reaction mixture was
stirred at room temperature for 90 min. The formed
precipitate was collected, washed with MeCN and n-
hexane and dried in vacuum. Yield: 207 mg
(0.60 mmol, 60%). Orange solid. M.p. 250–251 °C. IR:
3401, 3318, 3253, 3215, 3190, 2197, 1685, 1664, 1634,
1601, 1579, 1488, 1453, 1407, 1364, 1328, 1303, 1247,
1227, 1207, 1174, 1150, 1098, 1076, 1025, 951, 845,
779, 756, 745, 714, 671. 1H-NMR (300 MHz, (D6)DMSO)):
4.91 (1 H, s), 7.1–7.5 (6 H, m), 7.8–7.9 (3 H, m), 8.0–8.1
(1 H, m). 13C-NMR (75.5 MHz, (D6)DMSO)): 30.4, 56.0,
115.3–115.6 (m), 119.1, 120.9, 124.8, 125.8, 126.1,
129.1–129.2 (m), 130.2–130.9 (m), 134.2–134.6 (m),
149.5, 158.0, 159.7 (d, J=246 Hz), 176.8, 182.5. EI-MS:
346 (100) [M+ ], 302 (6), 251 (87), 223 (7), 173 (7), 105
(5), 76 (5). Anal. calc. for C20H11FN2O3 (346.32): C 69.36,
H 3.20, N 8.09; found: C 69.44, H 3.12, N 7.96.
2-Amino-4-(3,4-difluorophenyl)-5,10-dihydro-
5,10-dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile
(2e). 3,4-Difluorobenzaldehyde (142 mg, 1.0 mmol)
and malononitrile (70 mg, 1.0 mmol) were dissolved in
MeCN (5 mL) and three drops of Et3N were added. The
reaction mixture was stirred at room temperature for
30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg,
1.0 mmol) was added and the reaction mixture was
stirred at room temperature for 16 h. The formed
precipitate was collected, washed with MeCN and n-
hexane and dried in vacuum. Yield: 151 mg
(0.42 mmol, 42%). Orange solid. M.p. 260 °C. IR: 3403,
3331, 3290, 3256, 3195, 3073, 2206, 1664, 1656, 1639,
1620, 1606, 1594, 1581, 1517, 1438, 1412, 1363, 1332,
1302, 1284, 1274, 1244, 1204, 1179, 1153, 1117, 1096,
1076, 1039, 1021, 972, 950, 933, 900, 882, 865, 838,
820, 799, 790, 772, 763, 752, 730, 713, 673. 1H-NMR
(300 MHz, (D6)DMSO)): 4.67 (1 H, s), 7.2–7.5 (5 H, m),
7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). 13C-NMR (75.5 MHz,
(D6)DMSO)): 35.8, 56.9, 116.6-117.5 (m), 119.1, 120.7,
124.6, 125.8, 126.0, 130.7, 131.0, 134.1, 134.5, 141.4–
141.5 (m), 146.8–147.8 (m), 149.3, 150.0–151.1 (m),
158.2, 176.8, 182.6. EI-MS: 364 (100) [M+ ], 320 (6), 251
(91), 223 (8). Anal. calc. for C20H10F2N2O3 (364.31): C
65.94, H 2.77, N 7.69; found: C 66.02, H 2.61, N 7.80.
2-Amino-4-(3,5-difluorophenyl)-5,10-dihydro-
5,10-dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile
(2f). 3,5-Difluorobenzaldehyde (142 mg, 1.0 mmol) and
malononitrile (70 mg, 1.0 mmol) were dissolved in
MeCN (5 mL) and three drops of Et3N were added. The
reaction mixture was stirred at room temperature for
30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg,
1.0 mmol) was added and the reaction mixture was
stirred at room temperature for 16 h. The formed
precipitate was collected, washed with MeCN and n-
hexane and dried in vacuum. Yield: 165 mg
(0.45 mmol, 45%). Orange-red solid. M.p. 270 °C. IR:
3395, 3315, 3249, 3211, 3190, 3090, 2200, 1663, 1622,
1594, 1580, 1463, 1449, 1404, 1363, 1338, 1311, 1303,
1290, 1242, 1206, 1178, 1124, 1077, 1040, 1026, 1005,
991, 963, 944, 863, 838, 817, 772, 737, 728, 710, 682,
674. 1H-NMR (300 MHz, (D6)DMSO)): 4.70 (1 H, s), 7.0–
7.2 (3 H, m), 7.41 (2 H, s), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H,
m). 13C-NMR (75.5 MHz, (D6)DMSO)): 36.2, 56.6, 102.2–
102.9 (m), 110.8-111.1 (m), 119.0, 120.2, 125.8, 126.0,
130.8, 131.0, 134.1, 134.4, 148.1–148.3 (m), 149.6,
158.3, 162.4 (dd, J=13.1 Hz, 247 Hz), 176.7, 182.6. EI-
MS: 364 (96) [M+ ], 251 (100). Anal. calc. for
C20H10F2N2O3 (364.31): C 65.94, H 2.77, N 7.69; found: C
66.00, H 2.63, N 7.78.
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2-Amino-5,10-dihydro-5,10-dioxo-4-(2,4,5-tri-
fluorophenyl)-4H-naphtho[2,3-b]pyran-3-carboni-
trile (2g). 2,4,5-Trifluorobenzaldehyde (160 mg,
1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were
dissolved in MeCN (3 mL) and five drops of Et3N were
added. The reaction mixture was stirred at room
temperature for 30 min. Lawsone (174 mg, 1.0 mmol)
was added and the reaction mixture was stirred at
room temperature for 30 min. The formed precipitate
was collected, washed with MeCN and dried in
vacuum. Yield: 120 mg (0.31 mmol, 31%); Orange
solid. M.p. 274–275 °C. IR: 3411, 3318, 3220, 3194,
3059, 2208, 1660, 1640, 1626, 1606, 1593, 1515, 1427,
1412, 1369, 1332, 1316, 1302, 1266, 1245, 1208, 1185,
1158, 1142, 1094, 1070, 1019, 950, 899, 874, 846, 816,
761, 741, 715, 670, 620. 1H-NMR (300 MHz, CDCl3/(D6)
DMSO)): 4.85 (1 H, s), 6.46 (2 H, s), 6.8–6.9 (1 H, m),
7.0–7.1 (1 H, m), 7.6–7.7 (2 H, m), 7.8–7.9 (1 H, m),
8.0–8.1 (1 H, m). 13C-NMR (75.5 MHz, CDCl3/(D6)DMSO)
) δ 30.7, 56.4, 105.1–105.7 (m), 117.1–117.4 (m), 118.0,
120.5, 125.9, 126.0, 129.9, 130.6, 133.5, 134.1, 148.5,
158.5, 176.3, 181.8. EI-MS: 382 (100) [M+ ], 251 (92).
Anal. calc. for C20H9F3N2O3 (382.30): C 62.84, H 2.37, N
7.33; found: C 62.75, H 2.29, N 7.24.
2-Amino-5,10-dihydro-5,10-dioxo-4-(2,3,4,5,6-
pentafluorophenyl)-4H-naphtho[2,3-b]pyran-3-car-
bonitrile (2h). Pentafluorobenzaldehyde (196 mg,
1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were
dissolved in MeCN (3 mL) and five drops of Et3N were
added. The reaction mixture was stirred at room
temperature for 30 min. Lawsone (174 mg, 1.0 mmol)
was added and the reaction mixture was stirred at
room temperature for 30 min. The formed precipitate
was collected, washed with MeCN and dried in
vacuum. Yield: 131 mg (0.31 mmol, 31%). Orange
solid. M.p. 281–282 °C. IR: 3427, 3286, 3174, 2202,
1669, 1635, 1520, 1505, 1412, 1366, 1330, 1302, 1247,
1207, 1154, 1118, 1079, 1041, 1024, 992, 954, 937, 824,
790, 768, 719, 704, 648, 610. 1H-NMR (300 MHz, (D6)
DMSO) ) δ 5.13 (1 H, s), 7.66 (2 H, s), 7.8–8.0 (3 H, m),
8.0–8.1 (1 H, m). 13C-NMR (75.5 MHz, (D6)DMSO) ) δ
26.8, 52.6, 115.8, 118.7–118.9 (m), 125.9, 126.2, 129.7,
130.4, 130.9, 135.3, 138.4, 143.0, 146.4, 149.3, 159.5,
176.6, 182.2. EI-MS: 418 (100) [M+ ], 251 (75). Anal. calc.
for C20H7F5N2O3 (418.28): C 57.43, H 1.69, N 6.70;
found: C 57.30, H 1.62, N 6.61.
2-Amino-4-(3,4-dichlorophenyl)-5,10-dihydro-
5,10-dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile
(2i). 3,4-Dichlorobenzaldehyde (175 mg, 1.0 mmol) and
malononitrile (70 mg, 1.0 mmol) were dissolved in
MeCN (5 mL) and three drops of Et3N were added. The
reaction mixture was stirred at room temperature for
30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg,
1.0 mmol) was added and the reaction mixture was
stirred at room temperature for 16 h. The formed
precipitate was collected, washed with MeCN and n-
hexane and dried in vacuum. Yield: 135 mg
(0.34 mmol, 34%). Orange-red solid. M.p. 283–285 °C.
IR: 3396, 3328, 3196, 2203, 1658, 1638, 1605, 1593,
1471, 1411, 1362, 1333, 1294, 1243, 1207, 1177, 1157,
1127, 1093, 1079, 1029, 1017, 973, 948, 872, 834, 822,
793, 772, 750, 738, 728, 715, 682, 659, 617, 583. 1H-
NMR (300 MHz, (D6)DMSO)): 4.69 (1 H, s), 7.36 (1 H, dd,
J=8.8 Hz, 2.2 Hz), 7.40 (2 H, s), 7.64 (1 H, dd, J=8.3 Hz,
2.4 Hz), 7.42 (2 H, s), 7.57 (1 H, d, J=8.3 Hz), 7.64 (1 H,
d, J=2.4 Hz), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). 13C-
NMR (75.5 MHz, (D6)DMSO)): 35.8, 56.7, 119.1, 120.4,
125.8, 126.0, 128.3, 129.7, 129.8, 130.6, 130.8, 131.0,
131.1, 134.1, 134.5, 144.8, 149.4, 158.3, 176.8, 182.6. EI-
MS: 398 (15) [M+ ], 396 (23) [M+ ], 251 (61), 57 (100).
Anal. calc. for C20H10Cl2N2O3 (397.21): C 60.48, H 2.54,
N 7.05; found: C 60.32, H 2.48, N 7.11.
2-Amino-5,10-dihydro-4-[4-(methylthio)phenyl]-
5,10-dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile
(2j). 4-Methylsulfanylbenzaldehyde (152 mg, 1.0 mmol)
and malononitrile (70 mg, 1.0 mmol) were dissolved in
MeCN (5 mL) and three drops of Et3N were added. The
reaction mixture was stirred at room temperature for
30 min. The formed precipitate was dissolved by
heating the reaction mixture and 2-hydroxy-1,4-naph-
thoquinone (174 mg, 1.0 mmol) was added and the
reaction mixture was stirred at room temperature for
16 h. The formed precipitate was collected, washed
with MeCN and n-hexane and dried in vacuum. Yield:
280 mg (0.75 mmol, 75%). Orange-red solid. M.p.
266 °C. IR: 3398, 3319, 3248, 3211, 2194, 1691, 1655,
1638, 1604, 1593, 1494, 1409, 1365, 1336, 1303, 1238,
1208, 1179, 1162, 1097, 1077, 1041, 1026, 986, 986,
956, 945, 846, 833, 800, 771, 741, 720, 686. 1H-NMR
(300 MHz, (D6)DMSO)): 2.43 (3 H, s), 4.58 (1 H, s), 7.19
(2 H, d, J=8.6 Hz), 7.26 (2 H, d, J=8.6 Hz), 7.33 (2 H, s),
7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). 13C-NMR (75.5 MHz,
(D6)DMSO)): 14.6, 36.0, 57.3, 119.3, 121.8, 125.8, 126.1,
128.3, 130.6, 131.0, 134.1, 134.5, 148.8, 158.3, 176.9,
182.6. EI-MS: 374 (100) [M+ ], 327 (45), 251 (69). Anal.
calc. for C21H14N2O3S (374.41): C 67.37, H 3.77, N 7.48;
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(170 mg, 1.0 mmol) and malononitrile (70 mg,
1.0 mmol) were dissolved in MeCN (5 mL) and three
drops of Et3N were added. The reaction mixture was
stirred at room temperature for 30 min. 2-Hydroxy-1,4-
naphthoquinone (174 mg, 1.0 mmol) was added and
the reaction mixture was stirred at room temperature
for 16 h. The formed precipitate was collected, washed
with MeCN and n-hexane and dried in vacuum. Yield:
240 mg (0.61 mmol, 61%). Orange-red solid. M.p. 244–
245 °C. IR: 3402, 3320, 3251, 3212, 3071, 3046, 2937,
2896, 2195, 1691, 1663, 1665, 1639, 1603, 1593, 1563,
1481, 1412, 1363, 1336, 1300, 1279, 1238, 1207, 1179,
1153, 1096, 1065, 1040, 1026, 954, 931, 881, 838, 822,
803, 776, 761, 736, 719, 695, 685, 619, 561, 553. 1H-
NMR (300 MHz, (D6)DMSO)): 2.45 (3 H, s), 4.64 (1 H, s),
7.1–7.3 (3 H, m), 7.36 (2 H, s), 7.8–7.9 (3 H, m), 8.0–8.1
(1 H, m). 13C-NMR (75.5 MHz, (D6)DMSO)): 14.0, 35.8,
57.0, 114.2–114.5 (m), 119.1, 120.9, 123.7, 124.0, 124.4,
125.8, 126.0, 127.5, 130.7, 131.0, 134.1, 134.4, 142.9,
149.2, 158.3, 158.9 (d, J=242 Hz), 176.8, 182.6. EI-MS:
392 (100) [M+ ], 345 (28), 251 (82). Anal. calc. for
C21H13FN2O3S (392.40): C 64.28, H 3.34, N 7.14; found:
C 64.09, H 3.26, N 7.05.
2-Amino-5,10-dihydro-5,10-dioxo-4-[3-(penta-
fluoro-λ6-sulfanyl)phenyl]-4H-naphtho[2,3-b]pyran-
3-carbonitrile (2 l). 3-Pentafluorothiobenzaldehyde
(232 mg, 1.0 mmol) and malononitrile (70 mg,
1.0 mmol) were dissolved in MeCN (5 mL) and three
drops of Et3N were added. The reaction mixture was
stirred at room temperature for 30 min. 2-Hydroxy-1,4-
naphthoquinone (174 mg, 1.0 mmol) was added and
the reaction mixture was stirred at room temperature
for 16 h. The formed precipitate was collected, washed
with MeCN and n-hexane and dried in vacuum. Yield:
185 mg (0.41 mmol, 41%). Orange-red solid. M.p.
283 °C. IR: 3413, 3340, 3256, 3222, 3194, 3076, 2201,
1656, 1637, 1591, 1484, 1435, 1412, 1361, 1336, 1300,
1252, 1243, 1203, 1185, 1161, 1112, 1095, 1072, 1022,
945, 881, 839, 823, 805, 793, 780, 731, 718, 699, 687,
678. 1H-NMR (300 MHz, (D6)DMSO)): 4.84 (1 H, s), 7.43
(2 H, s), 7.5–7.6 (1 H, m), 7.6–7.7 (1 H, m), 7.7–7.9 (5 H,
m), 8.0–8.1 (1 H, m). 13C-NMR (75.5 MHz, (D6)DMSO)):
36.5, 56.8, 119.0, 120.5, 124.5, 125.0, 125.8, 126.1,
129.9, 130.7, 131.0, 131.9, 134.2, 145.4, 149.5, 152.9,
158.3, 176.8, 182.6. EI-MS: 454 (100) [M+ ], 326 (51), 251
(100). Anal. calc. for C20H11F5N2O3S (454.37): C 52.87, H
2.44, N 6.17; found: C 52.72, H 2.34, N 6.11.
2-Amino-4-(3-cyanophenyl)-5,10-dihydro-5,10-
dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile (2m).
3-Cyanobenzaldehyde (131 mg, 1.0 mmol) and malo-
nonitrile (70 mg, 1.0 mmol) were dissolved in MeCN
(3 mL) and three drops of Et3N were added. The
reaction mixture was stirred at room temperature for
30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg,
1.0 mmol) was added and the reaction mixture was
stirred at room temperature for 1 h. The formed
precipitate was collected, washed with MeCN and n-
hexane and dried in vacuum. Yield: 110 mg
(0.31 mmol, 31%). Red solid. M.p. 257 °C. IR: 3425,
3329, 3284, 3256, 3222, 3190, 2235, 2201, 1668, 1656,
1637, 1602, 1589, 1484, 1411, 1370, 1336, 1301, 1243,
1195, 1180, 1160, 1140, 1091, 1074, 7036, 1022, 955,
928, 815, 774, 756, 727, 716, 696. 1H-NMR (300 MHz,
(D6)DMSO)): 4.73 (1 H, s), 7.41 (2 H, s), 7.5–7.6 (1 H, m),
7.7–7.8 (2 H, m), 7.8–7.9 (4 H, m), 8.0–8.1 (1 H, m).
13C-NMR (75.5 MHz, (D6)DMSO)): 36.2, 56.8, 111.6,
118.7, 119.1, 120.4, 125.8, 126.0, 129.7, 130.8, 130.9,
131.4, 132.8, 134.1, 134.5, 145.3, 149.6, 158.3, 176.8,
182.6. EI-MS: 353 (94) [M+ ], 251 (100). Anal. calc. for
C21H11N3O3 (353.34): C 71.39, H 3.14, N 11.89; found: C
71.31, H 3.22, N 11.78.
2-Amino-4-(4-cyanophenyl)-5,10-dihydro-5,10-
dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile (2n).
4-Cyanobenzaldehyde (131 mg, 1.0 mmol) and malo-
nonitrile (70 mg, 1.0 mmol) were dissolved in MeCN
(3 mL) and three drops of Et3N were added. The
reaction mixture was stirred at room temperature for
30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg,
1.0 mmol) was added and the reaction mixture was
stirred at room temperature for 1 h. The formed
precipitate was collected, washed with MeCN and n-
hexane and dried in vacuum. Yield: 160 mg
(0.45 mmol, 45%). Red solid. M.p. 279–280 °C. IR: 3402,
3322, 3284, 3249, 3218, 3194, 2231, 2203, 1675, 1662,
1639, 1602, 1505, 1411, 1363, 1340, 1331, 1303, 1244,
1203, 1178, 1159, 1095, 1074, 1037, 1020, 949, 842,
797, 777, 752, 740, 721, 679. 1H-NMR (300 MHz, (D6)
DMSO)): 4.74 (1 H, s), 7.44 (2 H, s), 7.56 (2 H, dd, J=
8.4 Hz, 1.8 Hz), 7.78 (2 H, dd, J=8.4 Hz, 1.8 Hz), 7.8–7.9
(3 H, m), 8.0–8.1 (1 H, m). 13C-NMR (75.5 MHz, (D6)
DMSO)): 36.6, 56.5, 109.9, 118.7, 119.0, 120.7, 125.8,
126.1, 128.9, 130.7, 130.9, 132.6, 134.2, 134.5, 149.0,
149.5, 158.4, 176.7, 182.5. EI-MS: 353 (95) [M+ ], 251
(100). Anal. calc. for C21H11N3O3 (353.34): C 71.39, H
3.14, N 11.89; found: C 71.29, H 3.20, N 11.81.
2-Amino-4-(4-ethynylphenyl)-5,10-dihydro-5,10-
dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile (2o).
4-Ethynylbenzaldehyde (130 mg, 1.0 mmol) and malo-
nonitrile (70 mg, 1.0 mmol) were dissolved in MeCN
(3 mL) and three drops of Et3N were added. The
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reaction mixture was stirred at room temperature for
30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg,
1.0 mmol) was added and the reaction mixture was
stirred at room temperature for 1 h. The formed
precipitate was collected, washed with MeCN and n-
hexane and dried in vacuum. Yield: 114 mg
(0.32 mmol, 32%). Orange-red solid. M.p. >395 °C. IR:
3401, 3322, 3296, 3215, 2193, 1693, 1662, 1639, 1601,
1593, 1529, 1505, 1414, 1365, 1336, 1301, 1241, 1208,
1182, 1161, 1095, 1073, 1042, 1018, 963, 947, 849, 799,
779, 755, 744, 720, 693. 1H-NMR (300 MHz, (D6)DMSO)):
4.14 (1 H, s), 4.64 (1 H, s), 7.3–7.4 (6 H, m), 7.8–7.9
(3 H, m), 8.0–8.1 (1 H, m). 13C-NMR (75.5 MHz, (D6)
DMSO)): 57.0, 80.8, 83.2, 119.2, 120.5, 121.4, 125.8,
126.1, 128.1, 130.7, 131.0, 131.9, 134.2, 134.5, 144.5,
149.1, 158.4, 176.8, 182.6. EI-MS: 352 (100) [M+ ], 251
(81). Anal. calc. for C22H12N2O3 (352.35): C 74.99, H
3.43, N 7.95; found: C 75.10, H 3.31, N 7.82.
Toxoplasma gondii Cell Line, Culture Conditions and
Assay
Vero cells (ATCC® CCL81™, USA) were applied for the
cultivation of T. gondii tachyzoites of the RH strain. The
Vero cells in 96-Well plates were cultured in RPMI 1640
medium (5×103 cells/well in 200 μL) with 10% heat
inactivated fetal bovine serum (FBS, Invitrogen, USA)
in a humidified 5% CO2 atmosphere at 37 °C. The
inhibition assay with the T. gondii parasites in Vero
cells was carried out as described previously.[25,39]
Leishmania major Cell Isolation and Culture Conditions
Promastigotes of L. major were isolated in February
2016 and maintained in Schneider’s Drosophila me-
dium (Invitrogen, USA), which was supplemented with
10% FBS and antibiotics, in a tissue culture flask with
weekly transfers at 26 °C. Promastigotes were cryopre-
served in liquid nitrogen at concentrations of 3×106
parasite/mL. The virulence of L. major parasites was
maintained by passing in female BALB/c mice via
injection of 1×106 stationary-phase promastigotes in
the hind footpads. L. major amastigotes were isolated
from the treated mice after 8 weeks. The transforma-
tion of the isolated amastigotes into promastigotes
was achieved by culturing at 26 °C in Schneider’s
medium supplemented with 10% FBS and antibiotics.
Amastigote-derived promastigotes with less than five
in vitro passages were used for the infection of mice.
Male and female BALB/c mice were obtained from
Pharmaceutical College, King Saud University, Saudi
Arabia, and maintained in specific pathogen-free
facilities.[40,41] Concerning the mentioned laboratory
animals, we followed all the instructions and rules
designed by the Scientific Research Deanship, Qassim
University, Saudi Arabia, under the permission/accred-
itation number 10124-cosao-2020-1-3-I.
Leishmania major Cell Assays
Cell assays with L. major promastigotes and amasti-
gotes were carried out as described previously.[41–48]
Trypanosoma Cell Line and Culture Conditions
Cultivation of the T. b. brucei bloodstream form cell
strain Lister 427 was carried out in HMI-9 medium,
pH 7.5, supplemented with 10% FBS at 37 °C in a
humidified 5% CO2 atmosphere.
[3,42]
Alamar Blue (AB) Assay
Viable cells after treatment with drug candidates were
identified via the AB assay.[42–45] Pink resorufin is
formed in intact cells from the irreversible reaction of
the blue dye resazurin and NADH. T. b. brucei cells
(8000/well) were seeded on 96-well microplates, test
compounds (dissolved in DMSO) were added and the
cells were incubated for 72 h (5% CO2, 95% humidity,
37 °C). AB reagent (10 μL of 500 μM resazurin sodium
salt in PBS) was added and the cells were incubated
for additional 4 h at 37 °C. Fluorescence (extinction at
544 nm, emission at 590 nm) was determined on an
Omega FLUOstar (BMG Labtech) fluorescence plate
reader. The IC50 values were determined with the
Quest GraphTM IC50 Calculator (AAT Bioquest Inc.).
[47]
In Vitro Cytotoxicity Assay
MTT assay with Vero cells was carried out for
cytotoxicity evaluation of compounds. The assay was
carried out as reported previously.[47,48]
Antioxidant Assay
Aliquots of eight concentrations (1, 5, 10, 20, 25, 50,
100, and 150 μM) of test compounds dissolved in
methanol were added to eight test tubes. Compounds
were accurately dissolved in methanol to achieve the
required concentrations by dilution techniques. 5 mL
of 0.004% 1,1-diphenyl-2-picrylhydrazil (DPPH) solu-
tion was given to each test tube using a micropipette.
The solutions were kept at room temperature for
30 minutes to complete the reaction. DPPH was added
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to a blank test tube containing only methanol. After
30 min the absorbance was measured with a double
beam spectrophotometer (JASCO V-630) at 517 nm.
IC50 values were calculated from the plot of inhibition
(In %) vs. concentration (in μM).[46,47] The free radical
scavenging kinetics for standard antioxidant viz.
ascorbic acid and the test compounds were calculated
using the following formula:
DPPH scavenging effect ½%� ¼
½ðAcontrol   AsampleÞ=Acontrol� � 100
The biological activities of the ligands were exam-
ined in terms of DPPH radical scavenging activities
where the count fraction causing 50% inhibition of
DPPH is called IC50.
[49,50]
Cyclovoltammetry
Cyclic voltammograms were recorded of test com-
pounds dissolved in DMSO. Bioanalytical System BASi
EPSILON Model instrument with X-Y recorder was
applied with a three-electrode framework consisting of
a glassy carbon working anode, Ag+/AgCl as reference
electrode, a platinum wire as auxiliary electrode in
0.1 M Et4NClO4 as supporting electrode. Ferrocene
served as internal standard.[27] The direction of feed
potential was from anode to cathode.
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